Valosin-Containing Protein Contributes to Plexiform Neurofibroma Formation and Represents a Novel Therapeutic Target

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Neurofibromatosis type 1 (NF1) is a genetic disorder predisposing patients to plexiform neurofibromas (PNFs).
• The NF1 gene product, neurofibromin, interacts with p97/valosin-containing protein (VCP).

Purpose of the Study:

• To investigate the role of VCP in NF1-associated PNFs.
• To evaluate VCP inhibition as a potential therapeutic strategy for PNFs.

Main Methods:

• Cross-comparison of RNA sequencing and RUNX1-CHIP sequencing data.
• Co-immunoprecipitation, Western blot, and immunostaining.
• In vitro and in vivo studies using mouse models and pharmacological/genetic VCP inhibition.

Main Results:

• VCP was overexpressed in both mouse and human PNFs and interacts with neurofibromin.
• VCP inhibition led to proteotoxic stress, reduced PNF cell proliferation, and increased apoptosis.
• In vivo VCP inhibition significantly reduced PNF volume in mice.

Conclusions:

• VCP is a key player in NF1 PNF development and progression.
• VCP inhibition demonstrates significant preclinical efficacy, suggesting it as a potential novel therapeutic target for NF1 PNFs.